

ACMPR Licensed Producer

CSE: HUGE

OTCQB: FSDDF

FRA: OK9



Investor Presentation

October 2018

Forward Looking Statement

This presentation and the information contained herein are confidential and the property of FSD Pharma Inc. ("**FSD Pharma**"). This presentation is intended to introduce you to FSD Pharma. The information presented is not, and is not intended to be, an offer to sell or the solicitation of an offer to buy any security of FSD Pharma. It does not constitute an offer, solicitation or sale of any securities of FSD Pharma. It is not a prospectus or an offering memorandum.

Statements made are as of the date hereof; delivery of this presentation does not at any time create an implication that the information contained herein is accurate as of any date subsequent to today's date. FV Pharma has not undertaken any independent verification of industry data, trends, or third party information used herein.

This presentation contains forward looking information. These statements relate to future events, estimates, plan, expectations, forecasts, projections and future performance. Forward-looking statements are based on the opinions and assumptions of management as of the date made, and are subject to a variety of risks and other factors that could cause actual events/results to differ materially from these forward looking statements. Although management believes that the expectations are reasonable, there can be no assurance that such expectations will prove to be correct; these statements are no guarantee of future performance and involve known and unknown risks, uncertainties and other factors. We cannot guarantee future results, performance, or achievements and no representations are made that actual results achieved will be the same. Nothing herein can be assumed or predicted, and readers are strongly encouraged to learn more and seek independent advice before relying on any information presented.


Management's Mission

To Become The Largest
Hydroponic Indoor Cannabis
Facility In The World

Overview



Health Canada ACMPR
Licensed Producer
(as of October 2017)



Current Cultivation



Phase 1 Expansion Target:
Total - 820,000 sq.ft.




\$ 35 Million Cash and
Liquid Securities

No Debt



Joint Venture
With Auxly Cannabis
Group Inc. (TSX.V:XLY)



Phase 2 Expansion Target:
Total - 3,896,000 sq.ft.

How The Cannabis Giants Began

The World's 2 Largest Cannabis Companies (By Market Cap) Started By Acquisition Of Food Facilities.



®

Market Cap: \$15.290 Billion
Production Space: 2,800,000 sq. ft.
Location: Smith's Falls
Travel Time To Toronto: 3hrs 40mins



®

Market Cap: \$5.022 Billion
Production Space: 301,000 sq. ft.
Location: Leamington
Travel Time To Toronto: 3hrs 30mins



®

Market Cap: \$844 Million Approx.
Initial Production Space: 820,000 sq. ft.
Location: Cobourg
Travel Time To Toronto: 1 hour



Source: Canopy, Aphria and FSD Pharma – Market Cap: TMX Money as of September 12, 2018



Location Is The Key

Ontario's Feel Good Town - Only 1 hour drive east of Toronto

This is "HUGE"

The company is publicly traded under the symbol "HUGE" on the CSE




Former food
grade facility
100% Owned



Located off the 401
Highway in Cobourg,
1 hour east of Toronto



All under one roof to
promote lower cost
and economies of scale




70-acre parcel of land

27 acre – Plant
5 acre – Parking Lot
38 acre – Expansion Land



Cost Is King

- Maintaining tight costs is critical
 - having everything under one roof allows for:
 - greater economies of scale
 - less logistical issues
- Facility is only one hour from Toronto with major transportation access points
- Current building infrastructure valued at a replacement cost of \$78 Million as per appraisal



Railway line into the facility, capacity for 3 rail cars to come inside the plant

Area to build helipad – 15 minutes to downtown

Zoned Industrial

70 Acres

Large Scale Power On Site




Electrical substation
on site with 77000
Volts line coming to
the plant

Distributed in a bank
of 3 independent
subs of 13800 KVA
each

Can power over
9,000 x 1,000 watt
grow bulbs

Multiple natural Gas
lines on site (allows
cogeneration)

State Of The Art Facilities On Site



26 Loading
docks

Security fences
in place




2 separate major
water manes
into the facility

24 inch main
sewage pipe

Why Indoor Cannabis is Better than Greenhouse Cannabis

- In Recreational United States, the same strain that is grown by the same grower receives higher revenue per pound.
- Greenhouse flower will mainly be used to produce oils.
- Management margins for proper indoor grown cannabis will be higher than greenhouse over the next 3 years.
- Allows production quality and consistency 365 days per year while mitigating seasonal risks.
- There are no indoor grow competitors in Canada with nearly the same size footprint and there won't be.

Capacity To Meet Growing Demand



	Current	Expansion 1	Expansion 2
Total Facility (Sq.ft.)	25,000 Sq.ft.	820,000 Sq.ft.	3,896,000 Sq.ft.
Production Capacity	4,000 kg	Unlimited license	Unlimited license

Comparable Companies

Market Capitalization As Of September 12, 2018

Company	Symbol	Market Cap*	Footprint Sq.ft. - 2018	Expansion Capacity Sq.ft.
Canopy	WEED	\$15,290 MM	2,800,000	6,000,000
Emerald	EMH	\$770 MM	1,675,000	3,700,000
Aurora	ACB	\$8,648 MM	1,140,000	4,505,000
Cannttrust	TRST	\$1,247 MM	450,000	600,000
Aphria	APH	\$5,022 MM	300,000	1,000,000
Maricann	MARI	\$315 MM	217,000	852,000
Organigram	OGI	\$975 MM	217,000	880,000
Supreme	FIRE	\$578 MM	40,000	342,000
ABcann	ABCN	\$399 MM	15,000	165,000
FSD Pharma	HUGE	\$884 MM	25,000	3,896,000

*Source: TMX Money as of September 12, 2018

New Company Developments

- FSD Pharma has secured a \$7.5 Million Dollar financing at \$1 per share as part of existing strategic alliance with Auxly Cannabis Group Inc.
- The Horizons Marijuana Life Sciences Index ETF ("HMMJ: TSX") has added FSD Pharma as part of the quarterly rebalance of the constituent holdings.
- FSD Pharma was featured on CNBC's Cannabis Coverage. The live CNBC coverage bolsters the company's credibility in this competitive space. Companies featured on CNBC experience higher-than-average trading volume and may be added to important investor watchlists as credible opportunities.
- FSD Pharma made early stage investments with three of its strategic partners, based on the criteria of providing excellent investment potential and assisting FSD in business operations.
 - Investments in companies that will be public: High Tide Inc. (2M), Cannara Biotech, and SciCann Therapeutics (3M).




Joint Venture With Auxly Cannabis Group Inc. (TSX.V:XLY)

- XLY will 100% finance and construct the buildout of the former Kraft Facility with 55 million approved in Phase 1 development budget
- FV Pharma will operate and recover all costs plus 10%
- FV Pharma will receive 50.1% of all production
- Expected allocation will result in 200M Grams of Cannabis per annum for FV Pharma's Benefit (subject to full-capacity being achieved)
- Blue print rendering for first 220,000 sq. ft. now complete and expected to break ground in Q3 2018 with production by early 2019
- XLY to bring Management Expertise in:
 - Design, Development, Financing and Operations

Source: Global Newswire

The Auxly logo is displayed in a stylized, red, serif font. The letters are bold and closely spaced, with a slight shadow effect behind the text.

More “Joint” Venture Deals In The Pipeline



Strategic Investment:

Cannara Biotech Inc.

- FV Pharma is a large shareholder of Cannara and will occupy over 105,000 square feet of Cannara's 625,000 square foot facility, which sits on 27 acres of land
- Combined grow space of over 1.245 million square feet of indoor capacity
- Under way in the application process under the ACMPR and plans to be the largest indoor cultivation facility in Quebec
- Existing facility less than one hour drive from Montreal (Quebec's largest city)
- Please see more at <http://cannara.ca/about/>



Strategic Investment:

High-Tide Inc.

- A fully integrated retail distribution company
- Has 22 development permits for retail cannabis stores in Alberta and expects to open the maximum permitted number of 37 stores in the province. The company is awaiting its wholesale cannabis permit in Saskatchewan, expects to establish the maximum allowed number of 8 retail cannabis stores in British Columbia and intends to obtain a large number of retail licenses in Ontario.
- Owns 4 of Canada's most prominent retail brands: RGR Canada Inc., Smokers Corner (largest chain of cannabis accessory stores in Canada), Canna Cabana, and subject to shareholder approval, will own Famous Brandz)
- Please see more information on High-Tide Ventures at www.hightideinc.ca



HIGHTIDE

DEVELOPING RETAIL CANNABIS OPPORTUNITIES.

Collaboration and Profit Sharing Agreement

Canntab Therapeutics

- Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade cannabinoids. Canntab developed an in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release tablet dosages for therapeutic use.
- FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act. FSD pharma will provide 10,000 sqft of facility space at it's Cobourg facility.
- Canntab will provide FSD Pharma with 50% of the profits that are received on any retail sales of Canntab Products through channels that are established by FSD Pharma. Canntab may also purchase oil required for Products from FSD Pharma. In addition, Canntab will pay FSD Pharma a royalty of 3.5% of Canntab's sale price for all Canntab Products that are manufactured and sold from the premises.



Strategic Alliance:

SciCann Therapeutics

- SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products.
- FSD Pharma's wholly-owned subsidiary, FV Pharma, will invest up to \$3M for a 15% equity stake in SciCann.
 - With this, FV Pharma will receive an exclusive license in Canada for the production and distribution of a line of proprietary cannabinoid-based, patent pending and indication-specific products developed by SciCann.
- Dr. Zohar Koren, co-founder and CEO of SciCann is FSD Pharma's Head of Scientific Advisory Board
- Please see more on SciCann at <https://scicann.net/>



Technology

- Testing new world class lighting technology which could:
 - Lower energy costs and heat produced
- Food grade facility built to better deal with bug problems
- Novel technologies to deal with:
 - Bacteria
 - Mould, Mildew
 - Virus and VOC



Industry Developments

- Bill C-45, the *Cannabis Act* formally received Royal Assent in Canada's Parliament on June 21, 2018. The bill officially becomes law on October 17, 2018 when retail sales begin, according to an announcement by the federal government.

<https://www.newswire.ca/news-releases/fsd-pharma-inc-welcomes-official-passing-of-cannabis-act-in-canada-686274581.html>

- FSD Pharma will model its business plan after Big Pharma – focus on tight cost controls and economies of scale.



“HUGE” Catalysts

- Commenced trading on CSE May 2018 and has broken the Canadian all-time trading volume records for daily, weekly and monthly volumes on the CSE
- Currently growing cannabis in the facility
- FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
- Broke ground on 220,000 sq. ft. expansion with XLY Q3 2018
- Joint ventures for diversified products and distribution
- Recreational legalization fall of 2018
- Reach full production capacity in 2020

Capital Structure

Securities	Amount
Issued and Outstanding Basic:	1,319,600,458
Issued and Outstanding F/D:	1,531,842,915

Approx. \$53M Equity Capital Raised

- Raised exclusively through First Republic Capital Corp.
- Widely held with over 4,700 shareholders pre go public
- Raised all through individual accredited investors, not a single institutional investor

Management Team

Thomas Fairfull CEO, President and Executive Director	Michael Ash Chief Commercial Officer	Zeeshan Saeed Executive Vice President and Director	Anthony Durkacz Director	Donal Carroll Chief Financial Officer CPA, Director
Gerald Goldberg CPA, CA, Director	Vladimir Klacar Director	Dr. Raza Bokhari Director	Dr. Zohar Koren Head of Scientific Advisory Board	Sandy Huard Head of Investor Relations

For more information, please contact:

Investor Relations

ir@fsdpharma.com

www.fsdpharma.com

CSE: HUGE

OTC: FSDDF

FRA: 0K9